Sydbank: Expanded ALK approval is good news

From now on, ALK-Abelló will also be able to market its allergy tablet, Ragwitek, as suitable for children aged 5 and above in the US. Although this is of course good news, it isn't something that will generate a lot of sales in the short term, says senior analyst at Sydbank, Søren Løntoft Hansen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK gains important approval on difficult US market
For subscribers
ALK has decent growth forecast in sight
For subscribers